You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
|
|---|---|
| Published in |
Journal of Translational Medicine, April 2013
|
| DOI | 10.1186/1479-5876-11-89 |
| Pubmed ID | |
| Authors |
Satoshi Wada, Christopher M Jackson, Kiyoshi Yoshimura, Hung-Rong Yen, Derese Getnet, Timothy J Harris, Monica V Goldberg, Tullia C Bruno, Joseph F Grosso, Nicholas Durham, George J Netto, Drew M Pardoll, Charles G Drake |
| Abstract |
The FDA recently approved an anti-CTLA-4 antibody (Iplimumab) for the treatment of metastatic melanoma. This decision was based on Phase III results, which demonstrate that blocking this immune checkpoint provides a survival advantage in patients with advanced disease. As a single agent, ipilimumab is also being clinically evaluated in advanced (metastatic, castrate-resistant) prostate cancer and two randomized, placebo-controlled Phase III studies have recently completed accrual. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Russia | 1 | 50% |
| United States | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 87 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 17% |
| Student > Ph. D. Student | 13 | 15% |
| Student > Master | 11 | 13% |
| Student > Bachelor | 10 | 11% |
| Other | 8 | 9% |
| Other | 13 | 15% |
| Unknown | 17 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 34% |
| Agricultural and Biological Sciences | 12 | 14% |
| Biochemistry, Genetics and Molecular Biology | 10 | 11% |
| Immunology and Microbiology | 6 | 7% |
| Computer Science | 3 | 3% |
| Other | 6 | 7% |
| Unknown | 20 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2014.
All research outputs
#18,942,832
of 24,143,470 outputs
Outputs from Journal of Translational Medicine
#2,956
of 4,294 outputs
Outputs of similar age
#148,585
of 202,943 outputs
Outputs of similar age from Journal of Translational Medicine
#45
of 54 outputs
Altmetric has tracked 24,143,470 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,294 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,943 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.